Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study

CONCLUSION: In patients with high VEGF-D, ramucirumab demonstrated a greater improvement in OS and PFS versus placebo; however, baseline VEGF-D level was not predictive of ramucirumab OS benefit using VEGF-D assay for IUO. The RAISE intent-to-treat results remain valid.PMID:34229554 | DOI:10.1080/03007995.2021.1940908

Source: Current Medical Research and Opinion - July 7, 2021 Category: Research Authors: Hiroya Taniguchi Takayuki Yoshino Kensei Yamaguchi Kentaro Yamazaki Andrew B Nixon Josep Tabernero Eric Van Cutsem Kim R Robling Paolo B Abada Rebecca R Hozak Robert Siegel Jeffrey A Fill Sameera Wijayawardana Richard A Walgren Brendan Giles Abby Jones Ke Source Type: research